ATRA completed a major strategic pivot by winding down CAR-T programs and achieving profitability while significantly reducing operations and cash position.
The company executed a dramatic turnaround from -$85.4M net loss to +$32.7M profit by discontinuing expensive CAR-T development programs and focusing on commercializing tab-cel in Europe through its Pierre Fabre partnership. However, the 66% decline in cash to just $8.5M and 81% reduction in total assets signals a much smaller, capital-constrained operation that may face funding challenges despite current profitability.
ATRA achieved a remarkable financial transformation, swinging from -$85.4M net loss to +$32.7M profit primarily by slashing R&D expenses 75% from $151.5M to $37.4M through program discontinuations. The company dramatically downsized its balance sheet with total assets falling 81% to $20.2M and current liabilities declining 89% to $14.9M, while cash dropped 66% to just $8.5M. This represents a successful but dramatic restructuring that eliminated losses but left the company operating with minimal resources and a much smaller operational footprint.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Net income grew 138.3% — bottom-line growth signals improving overall business health.
Current liabilities reduced — improved short-term financial position and working capital health.
Total assets contracted 81.5% — asset sales, write-downs, or balance sheet optimization underway.
Current assets declined 81.2% — monitor working capital adequacy and short-term liquidity.
R&D spending cut 75.3% — could signal cost discipline or concerning reduction in innovation investment.
Liabilities reduced 71.5% — deleveraging improves balance sheet strength and financial flexibility.
Cash declined 66.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Equity base grew 60.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Operating cash flow grew 25.9% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →